NIKKEI 225
37,946.66 +318.18 (+0.85%) HANG SENG
17,626.75 +342.21 (+1.98%) CRUDE OIL
83.86 +0.29 (+0.35%) GOLD FUTURES
2,348.40 +5.90 (+0.25%) DOW
38,085.80 -375.12 (-0.98%) Bitcoin GBP
51,408.10 -17.66 (-0.03%)
Indivior PLC (INDV.L)
| Previous close | 1,514.00 |
| Open | 0.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 481,011 |
| Market cap | 1.897B |
| Beta (5Y monthly) | 0.02 |
| PE ratio (TTM) | 1,400.00 |
| EPS (TTM) | 0.01 |
| Earnings date | 25 Jul 2024 - 29 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 16 Jun 2016 |
| 1y target est | 24.62 |
ZacksIndivior PLC (INDV) Q1 Earnings and Revenues Lag Estimates
Indivior (INDV) delivered earnings and revenue surprises of -2.63% and 5.33%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
CityAMDrugmaker Indivior seeks shareholder approval to move primary listing from London to New York
Opioid dependence treatment maker Indivior has confirmed a plan to move its primary stock market listing from London to New York this summer in yet another blow to the capital's beleaguered bourse.
- Reuters
UK-listed drugmaker Indivior seeks shareholder nod for US listing
Indivior had, in February, announced its intent to shift its listing by the middle of the year to the U.S., which, it argued, reflected its growth opportunities as its proprietary treatments are U.S.-centred and U.S.-based investors account for nearly 50% of its overall shareholder base. The list of UK-based companies that have already listed in the United States includes ARM, the UK's biggest chip company, as well as building supplies firm CRH and plumbing equipment company Ferguson. Indivior also reaffirmed its annual outlook after logging in a 12% net revenue growth in the first quarter, boosted by strong demand for its Sublocade treatment for opioid use disorder.
